← Back to Search

Behavioural Intervention

Attentional-Control Training for Sickle Cell Disease (ACT Trial)

N/A
Recruiting
Led By Steven J Hardy, Ph.D.
Research Sponsored by Children's National Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 10 months
Awards & highlights

Summary

This trial is studying the effectiveness of a game-like program to help children with sickle cell disease improve their attention.

Eligible Conditions
  • Sickle Cell Disease
  • Attention Deficit Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 10 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 10 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
EndeavorRx feasibility assessed by patient/family interest
EndeavorRx feasibility assessed by program completion rates
EndeavorRx feasibility assessed by reports of technical ease-of-use and satisfaction
Secondary study objectives
Inattention assessed by change in Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3)
Inattention assessed by change in the Inattention subscale of the ADHD Rating Scale, Fifth Edition (ADHD-RS-V)

Trial Design

1Treatment groups
Experimental Treatment
Group I: EndeavorRxExperimental Treatment1 Intervention
Children will be asked to begin attentional control training at home within two weeks of baseline testing and to complete 6 training missions per day (25-30 minutes), 5 days per week, for 4 weeks (total = 120 training missions).

Find a Location

Who is running the clinical trial?

Children's National Research InstituteLead Sponsor
218 Previous Clinical Trials
257,890 Total Patients Enrolled
Steven J Hardy, Ph.D.Principal InvestigatorChildren's National Research Institute

Media Library

EndeavorRx (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05099874 — N/A
Sickle Cell Disease Research Study Groups: EndeavorRx
Sickle Cell Disease Clinical Trial 2023: EndeavorRx Highlights & Side Effects. Trial Name: NCT05099874 — N/A
EndeavorRx (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05099874 — N/A
~7 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top